Johnson Investment Counsel’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Johnson Investment Counsel’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-43,600	Closed	-$419K	–	854
2024 Q4	$419K	Hold	43,600	–	–	﹤0.01%	562
2024 Q3	$125K	Hold	43,600	–	–	﹤0.01%	786
2024 Q2	$127K	Sell	43,600 -3,158	-7%	-$8.64K	﹤0.01%	741
2024 Q1	$149K	Hold	46,758	–	–	﹤0.01%	737
2023 Q4	$157K	Hold	46,758	–	–	﹤0.01%	691
2023 Q3	$111K	Hold	46,758	–	–	﹤0.01%	658
2023 Q2	$82.3K	Hold	46,758	–	–	﹤0.01%	660
2023 Q1	$144K	Hold	46,758	–	–	﹤0.01%	642
2022 Q4	$248K	Hold	46,758	–	–	﹤0.01%	587
2022 Q3	$165K	Hold	46,758	–	–	﹤0.01%	618
2022 Q2	$121K	Hold	46,758	–	–	﹤0.01%	630
2022 Q1	$209K	Hold	46,758	–	–	﹤0.01%	634
2021 Q4	$318K	Hold	46,758	–	–	﹤0.01%	550
2021 Q3	$341K	Hold	46,758	–	–	﹤0.01%	520
2021 Q2	$469K	Hold	46,758	–	–	0.01%	454
2021 Q1	$447K	Buy	+46,758	New	+$459K	0.01%	441

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Johnson Investment Counsel's PSTX Position: Q1 2025 in Review

Johnson Investment Counsel sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 43,600 shares — an estimated $419K sold.

Johnson Investment Counsel first reported a position in PSTX in Q1 2021 and held it in 16 quarters. The position peaked at $469K in Q2 2021. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Johnson Investment Counsel reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Johnson Investment Counsel sold 43,600 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $419K.
Johnson Investment Counsel first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2021 and held it in 16 quarters.
Johnson Investment Counsel's Poseida Therapeutics, Inc. Common Stock position peaked at $469K in Q2 2021.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Johnson Investment Counsel's 13F filing for Q1 2025, filed 21 Apr 2025.